Quote | Inventiva S.A. (NASDAQ:IVA)
Last: | $3.29 |
---|---|
Change Percent: | -1.52% |
Open: | $3.35 |
Close: | $3.29 |
High: | $3.35 |
Low: | $3.28 |
Volume: | 3,908 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | Inventiva S.A. (NASDAQ:IVA)
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...
Message Board Posts | Inventiva S.A. (NASDAQ:IVA)
Subject | By | Source | When |
---|---|---|---|
What happened over here? Talk about a rocket launch! | bigbux1 | investorshub | 10/07/2022 7:44:44 PM |
going to a stinky pinky...lol | loniee | investorshub | 12/02/2010 5:44:29 PM |
holy cow...teach me to pull it off of | loniee | investorshub | 07/17/2010 1:40:24 PM |
ValueRich Substantially Increases Its Cash Position | THUMBS | investorshub | 07/16/2010 7:45:57 PM |
LOL, been awhile | THUMBS | investorshub | 04/14/2010 4:24:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Inventiva S.A. Company Name:
IVA Stock Symbol:
NASDAQ Market:
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceu...
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 millio...